Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

22%

2 trials in Phase 3/4

Results Transparency

0 of 7 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

3(50.0%)

Phase 4

2(33.3%)

Phase 2

1(16.7%)

6Total

N/A(3)

Phase 4(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT01869595Completed

Thai MSM/TG Test and Treat Study

Role: collaborator

NCT06211686Not ApplicableUnknown

The Effectiveness of a Health Promotion Program for Older People With Post-Covid-19 Sarcopenia

Role: collaborator

NCT02383602Completed

Study to Evaluate the Feasibility of Community-based Test and Treat Strategies Among Men Who Have Sex With Men and Transgender Women to Increase the Uptake of HIV Testing and Treatment Services in Thailand

Role: collaborator

NCT01225406Completed

Third Line Highly Active Antiretroviral Therapy (HAART) in HIV-infected Children

Role: collaborator

NCT00627055Phase 4Completed

Second-line Therapy Antiretroviral in Patients Who Failed Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) - Based Regimens

Role: collaborator

NCT01159223Phase 4Completed

Low Dose Atazanavir/r Versus Standard Dose Atazanavir/r (LASA)

Role: collaborator

NCT01644370Not ApplicableCompleted

Children With HIV and Asthma (CHIVAS)

Role: collaborator

NCT01656109Phase 2Completed

Atazavanir/Ritonavir-based HAART in Children

Role: collaborator

NCT01364675Not ApplicableUnknown

Primary Prevention of Cardiovascular Disease (CVD) in Pre-diabetic & Pre-hypertensive Subjects

Role: collaborator

All 9 trials loaded